Chapter 7. Genetics of Laminopathies
- Derek J. Chadwick Organizer,
- Jamie Goode
Published Online: 7 OCT 2008
DOI: 10.1002/0470093765.ch7
Copyright © Novartis Foundation 2005
Book Title

Nuclear Organization in Development and Disease: Novartis Foundation Symposium 264
Additional Information
How to Cite
Yaou, R. B., Muchir, A., Arimura, T., Massart, C., Demay, L., Richard, P. and Bonne, G. (2008) Genetics of Laminopathies, in Nuclear Organization in Development and Disease: Novartis Foundation Symposium 264 (eds D. J. Chadwick and J. Goode), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/0470093765.ch7
Publication History
- Published Online: 7 OCT 2008
- Published Print: 14 JAN 2005
ISBN Information
Print ISBN: 9780470093733
Online ISBN: 9780470093764
- Summary
- Chapter
Keywords:
- laminopathies;
- encoding A-type lamins;
- LMNA mutations;
- Emery-Dreifuss muscular dystrophy (EDMD);
- familial partial lipodystrophy of Dunningan (FPLD);
- Mandibuloacral Dysplasia (MAD);
- genetics of laminopathies;
- X-linked and autosomal dominant (XL- and AD-EDMD)
Summary
Laminopathies are now recognized as a group of disorders due to mutations of the LMNA gene, which encodes A-type lamins. Primarily, mutations in LMNA have been associated to the autosomal forms of Emery-Dreifuss muscular dystrophy, a rare slowly progressive humero-peroneal muscular dystrophy accompanied by early contractures and dilated cardiomyopathy with conduction defects. LMNA mutations have been reported to be responsible for up to 10 distinct phenotypes that affect specifically either the skeletal and/or cardiac muscle, the adipose tissue, the peripheral nervous tissue, the bone tissue or more recently premature ageing. So far more than 180 different LMNA mutations have been identified in 903 individuals. The first studies of phenotype/genotype relationships revealed no clear relation between the phenotype and the type and/or the localization of the mutation, except perhaps for the globular tail domain of lamins A/C. Studies of the consequences of LMNA mutations in the skin cultured fibroblasts from the patients reveal abnormal nuclei in variable proportions, with dysmorphic nuclei exhibiting abnormal patterns of expression of B-type lamins and emerin. Finally, the development of KO and KI LMNA mice, will certainly give further insight into the pathophysiological mechanisms associated with LMNA mutations. For example, LmnaH222P/H222P mice harbour phenotypes reminiscent of Emery-Dreifuss muscular dystrophy.
